Sickle cell disease receives two FDA approved gene therapies in December of 2023 for patients aged 12 years and older. Sickle cell disease is a genetic disorder that impacts about 100,000 patients in the US and is attributed with premature death. Although commonly thought of in the African American population, it can occur across ethnicities impacting men and women the equally. Both therapies, Casgevy & Lyfgenia, are anticipated to cost upwards of $2 million. Despite being touted as “one-time” treatments, patients and caregivers will require immense support to endure the intensive processes (requiring months to complete) the associated intensive chemotherapy and prolonged hospitalization. Lyfgenia carries a black box risk of cancer. Clinical trials are on-going. Please consult your pharmacy expertise for specific case review or questions.
top of page
bottom of page
Opmerkingen